GlassScriptPhysician profile
Jennifer Chima
NPI 1881126555
$3,896.44
in general payments reported to CMS, 2019-2025
45 companies · $71.82 in 2025
The $71.82 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $401 · 2023: $2,251 · 2024: $1,173 · 2025: $71.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,495.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $408.56 | 2022-2025 | |
| Ucb, INC. | $384.24 | 2022-2024 | Briviact, Rystiggo, Nayzilam |
| Biogen, INC. | $241.12 | 2023-2024 | Vumerity, Plegridy, Avonex |
| Alexion Pharmaceuticals, INC. | $221.12 | 2022-2024 | Ultomiris, Soliris |
| Abbvie INC. | $212.54 | 2022-2025 | Botox, Ubrelvy, Qulipta |
| Jazz Pharmaceuticals INC. | $209.71 | 2022-2024 | Epidiolex, Xywav |
| Csl Behring | $180.44 | 2023-2024 | Hizentra |
| Lundbeck LLC | $155.46 | 2022-2024 | Vyepti |
| Otsuka America Pharmaceutical, INC. | $149.79 | 2023-2024 | Rexulti, Nuedexta |
| Merz Pharmaceuticals, LLC | $128.08 | 2022-2023 | Xeomin |
| Pfizer INC. | $109.12 | 2023-2024 | |
| Emd Serono, INC. | $105.52 | 2023 | Mavenclad |
| Argenx US, INC. | $98.47 | 2023 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $98.44 | 2022-2024 | Amyvid, Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $94.83 | 2022-2024 | Ajovy, Austedo Xr |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Chima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.